The Synthetic Biology Market size is estimated to be valued at USD 21.90 Bn in 2025 and is expected to reach USD 90.73 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2032.
To learn more about this report, Download Free Sample
The scope of the Synthetic Biology Market is poised for rapid advancement due to new developments in DNA sequencing as well as gene-editing technologies. Such advancements increase the applicability of synthetic biology in healthcare, particularly with CRISPR-based therapies for genetic disorders. An example is the approval of Casgevy, the first CRISPR-based treatment for sickle-cell disease issued by Vertex Pharmaceuticals and CRISPR Therapeutics. Ongoing research in synthetic DNA and RNA for drug discovery as well as genome engineering is driving the expansion of the market.
|
Event |
Description and Impact |
|
U.S.-China Technology Trade Tensions and Export Controls |
|
|
EU Regulatory Framework Evolution for Biotechnology |
|
|
Breakthrough AI Integration in Biological Design |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
By transforming the biological system design and engineering processes, artificial intelligence (AI) is profoundly altering the synthetic biology landscape. The intersection of AI and synthetic biology converges innovation cycles across multiple fields including pharmaceuticals, agriculture, and industrial biotechnology, as well as more futuristic domains like ocean-cleaning synthetic biology and algae bioengineering. It also reduces development costs and enables previously impossible applications.
Integrating AI technologies creates a new model for biological design as they shift away from predictive and data-driven work to intuition and trial-and-error. In synthetic biology, sophisticated machine learning models parse massive datasets of genetic sequences, protein structures, metabolic pathways, and CRISPR tools, rapidly resolving unique problems and accelerating progress in biological engineering.
For example, Ginkgo Bioworks exemplifies this transformation through its AI-powered "organism foundry" platform, which combines automated laboratory systems with machine learning to predict genetic modifications that yield desired biological outcomes. This approach has compressed organism development timelines from years to months and enabled scalable applications ranging from fragrance production to pharmaceutical manufacturing and climate change solutions.
AI-driven applications span protein engineering, metabolic pathway optimization, and drug discovery. Zymergen (now part of Gensyn) leverages AI to optimize microbial strains producing high-value chemicals and materials, achieving over 50% improvements in bio-based production efficiency compared to traditional methods. Their platform’s capacity to analyze thousands of genetic variants simultaneously is also critical for advancing synthetic biology in algae bioengineering—enhancing biofuel production and carbon capture.
Product innovation fueled by AI is democratizing synthetic biology by making complex engineering accessible to a broader spectrum of researchers and organizations. Twist Bioscience’s AI-driven DNA synthesis platform, for example, uses machine learning to optimize DNA sequence design and preempt synthesis errors, improving accuracy rates to over 99.9% and reducing costs by approximately 90%. This innovation empowers researchers to undertake more ambitious projects, such as developing synthetic biology approaches for ocean cleanup and creating climate change mitigation solutions.
As AI continues to mature and converge with cutting-edge tools like CRISPR in synthetic biology, its impact will further expand, enabling more precise, efficient, and sustainable biological engineering applications that address global challenges across health, environment, and industry.
By 2030, the synthetic biology market is projected to reach $65.1 billion which is a tremendous increase considering it was valued $22.5 billion in 2023. Like all other markets, the synthetic biology market is also influenced by R&D expenses, regulatory policies, and manufacturing intricacies. Premium pricing is common for innovative technologies but as they mature and scale, solutions become more affordable. For DNA Synthesis and Oligonucleotides, the pricing is from $0.05 to $0.30 per base pair which depends on the provider and product specifications.
The synthesis of genes is priced at $1,500 to $8,000, which is quite varied considering it depends on length and cloning needs. More complex synthetic genome projects can go up to 1 million dollars for mammalian reconstruction pathways. The biology tools also have competitive pricing. CRISPR kits are priced from $65 to $800 while cloning and protein expression kits range from $150 to $2,500. Design tools and other software have subscription based pricing which starts from 49 dollars monthly per user to even 500 thousand dollars for large scale projects. The engineered organisms and cell lines are priced between 5,000 to 100,000 dollars which makes sense considering the wide range of complexity and customization required.
Feedback from crucial end users like IVF clinics and biotechnology and pharmaceutical companies, research and academic institutions, and biobanks illustrates the increasing adoption of synthetic biology innovations to foster new developments and enhance outcomes across various applications.
IVF clinics indicate a rising use of synthetic biology in genetic screening and embryo selection due to improved accuracy, faster turnaround times, and increased patient success rates.
Cost effectiveness and regulatory barriers are noted as concerns by some clinics, though overall synthetic biology adoption is on the rise. Biotechnological and pharmaceutical companies stress the importance of synthetic biology’s capabilities in drug discovery, biomanufacturing, and personalized therapeutics.
Users appreciate advances in AI-driven design platforms and gene editing technologies like CRISPR, though concerns about scalability and integration with existing workflows persist. Research and academic institutions see value in synthetic biology (synbio) platforms for fundamental research and innovation, especially in DNA synthesis and genome editing.
Limited funding and a lack of adequate training pathways pose challenges for researchers pursuing cross-disciplinary work. From the Perspective of biobanks, synthetic biology serves an important role in the creation of standardized biological materials as well as complex engineered cell lines, enhancing reproducibility and quality control. Focus areas continue to include data transparency, and ethics of genetic modification.
Overall, end users express optimism about the expanding capabilities of synthetic biology while calling for continued support in cost reduction, regulatory clarity, and user education.
To learn more about this report, Download Free Sample
Changes in public awareness of synthetic biology lead to an increase in the demand for synthetic biology products. Thus, key players in the market are engaged in investing in strategic development such as acquisition, collaboration, etc. in order to expand their business and address the demand.
For instance, in November 2020, Codexis, Inc., a leading synthetic biology company in collaboration with a leading life science investor, Casdin Capital, announced the launch of SynBio Innovation Accelerator. Sumitomo Chemical is one of the leading players in Japan, and it launched SynBio Hub, a new organization in the U.S. to accelerate next-generation business utilizing synthetic biology.
With the advent of new breakthrough technologies like Clustered regularly interspaced short palindromic repeats (CRISPR), synthetic biology is poised to revolutionize how healthcare issues are addressed. Techniques like CRISPR allow researchers to easily edit genes and regulate the expression of genetic material with unprecedented precision.
This has enormous potential to treat many diseases that were previously incurable. Conditions like sickle cell anemia, cystic fibrosis, and various types of cancer which have genetic origins could potentially be corrected at the DNA level. Companies are actively pursuing therapies using genome editing for clinical applications.
CRISPR also enables the synthesis of entirely new genetic codes that do not exist in nature. Scientists are learning to programme and assemble DNA the way computers are programmed. This will allow engineering cells and biological systems with customized functions. Researchers have synthesized bacterial genomes from scratch as a proof of concept and more complex genomes will be achieved. Such advanced forms of genome engineering will drive the synthetic biology market as it opens up new paradigms for diagnosing, preventing and curing diseases.
Pharmaceutical firms are investing heavily in genome editing research to develop genetically targeted treatments. As the technology matures, it will make personalized medicine a reality by allowing genetic corrections to be made for each individual's unique genetic profile.
The ability to program cells to target specific diseases opens possibilities for advanced diagnostics and personalized treatments. Synthetic biology tools allow engineering cells for regenerative medicine and 3D printing living tissues. Production of therapeutic proteins, antibodies, and vaccines through cellular engineering rather than livestock/crop cultivation promises sustainability. Lowering drug development costs through the precision of synthetic engineering attracts pharmaceutical investment.
The product segment includes oligonucleotides, enzymes, synthetic cells, chassis organism, and others. Oligonucleotides is anticipated to hold 28.3% of the market share in 2025. Oligonucleotides are short strands of synthetic nucleic acids that can be modified to target specific genes. Their high specificity makes them a valuable tool for treating conditions at the genetic level.
As our understanding of genomics advances, more drug developers are utilizing oligonucleotides to combat diseases. Their programmable nature allows designing therapies that interfere with or modify target mRNA and regulate gene expression. Areas like oncology have seen promising results with oligonucleotide drugs that can block proteins driving cancer progression. Their ability to impact single genes with precision makes them well-suited for an era focused on personalized healthcare.
More drug makers are incorporating oligonucleotides into pipelines as the benefits of tailored treatments for rare diseases and various cancers become clear. Their usage is poised to expand further as genomic research uncovers new targets and delivery methods to optimize oligonucleotide potency continue evolving.
The technology segment includes genome engineering, PCR technology, bioprocessing technology, NGS technology, bioinformatics, nanotechnology, and others. The PCR technology segment is expected to hold 26.1% of the market share in 2025. The polymerase chain reaction (PCR) technique is a cornerstone of modern biotechnology that amplifies snippets of DNA across billions of copies. It allows detecting rare gene variants and pathogens, validating transgenic organisms, and quantifying genetic material.
Since its introduction in the 1980s, continuous improvements have made PCR more sensitive and high-throughput. Its ability to rapidly make millions of copies of specific DNA sequences in an automated process accelerates research goals. Academia and industry rely on PCR for tasks like validating recombinant DNA constructs, screening cell lines, and underpinning diagnostic tests.
As understanding of genomics and personalized medicine grows, PCR fuels discovery by facilitating analysis of genetic sequences. Its versatility and high reproducibility have cemented its role in basic research as well as application areas such as forensics. Advancements like quantitative PCR and droplet digital PCR further multiplier PCR’s utility.
The end user segment includes pharmaceutical companies, biotechnology companies, CMO & CRO, and others. Biotechnology companies contribute the highest share of the synthetic biology market and is projected to hold 34.1% of the market share in 2025.
Biotech firms play a pivotal role in leveraging the latest tools from synthetic biology and associated fields to develop innovative therapeutics. They house dedicated R&D divisions exploring how techniques such as oligonucleotide engineering, gene editing and cellular reprogramming can combat disease.
Many biotechs have pipelines centered on harnessing these technologies, whether developing new gene or cell therapies or engineering microbes to produce pharmaceutical ingredients. Compared to large pharmaceutical corporations, biotechs have more flexibility pursuing high-risk ventures with potential for step-change results.
Successful examples include utilizing CRISPR for developing crops resistant to herbicides as well as engineering immune cells to treat cancer. The innovative nature of synthetic biology lends itself well to biotech’s ability to pivot rapidly between research areas. As healthcare increasingly relies on customized solutions, biotech firms’ focus on applying emerging platforms serves as a key driver for continued synthetic biology adoption in drug discovery.
To learn more about this report, Download Free Sample
North America is poised to lead the global synthetic biology market, holding an estimated 42.3% share in 2025. The region’s dominance is driven by substantial R&D investments from major biotechnology firms based in the United States and Canada, with a strong focus on advancing gene and cell therapies using cutting-edge synthetic biology platforms.
The presence of world-class academic research centers, along with robust government initiatives such as funding from the National Institutes of Health (NIH), continues to accelerate innovation and translational research. This well-established biotechnology ecosystem, combined with access to capital and a skilled workforce, is expected to support sustained market expansion across North America.
Asia Pacific is emerging as the fastest-growing region in the global synthetic biology market, propelled by rapidly advancing economies such as China and India. The region is witnessing a surge in public and private investments aimed at strengthening domestic synthetic biology capabilities and infrastructure.
China, in particular, is making coordinated efforts to position itself as a global leader through strategic initiatives like the GIDL projects. Additionally, competitive manufacturing costs, a growing base of scientific talent, and increasingly favorable regulatory environments are attracting global biotech firms to establish R&D centers and production hubs. Rising demand for advanced healthcare solutions and biologic therapies across the region is expected to fuel continued growth.
The U.S. leads the North American synthetic biology market, backed by strong federal support and a thriving innovation ecosystem. Major companies are integrating synthetic biology into drug development, bio-based materials, and precision medicine, driving continuous advancements across healthcare and industrial sectors.
China stands at the forefront of synthetic biology growth in Asia Pacific. National programs supporting genome engineering and bio-manufacturing, along with rapid infrastructure development, are accelerating the adoption of synthetic biology across various applications, from pharmaceuticals to sustainable chemicals.
India’s synthetic biology market is expanding quickly, supported by a rising focus on healthcare innovation, increasing public health investment, and cost-efficient R&D. Government-backed initiatives and a strong scientific community are positioning India as a key contributor to regional market momentum.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 21.90 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 22.5% | 2032 Value Projection: | USD 90.73 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Synbio Technologies, Merck KGaA, Agilent Technologies Inc., GenScript, Amyris, Eurofins Genomics GmbH, Integrated DNA Technologies Inc., Codexis Inc., EnBiotix Inc., Synthego, New England Biolabs (UK) Ltd., Scarab Genomics LLC , Genomatica Inc., Novonesis Group, Bota Bio, Creative Biogene, and Illumina, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
